Past, present, and future of cell replacement therapy for parkinson's disease: a novel emphasis on host immune responses

Tae-Yoon Park,Jeha Jeon,Young Cha,Kwang-Soo Kim

DOI: https://doi.org/10.1038/s41422-024-00971-y

IF: 44.1

2024-05-23

Cell Research

Abstract:Parkinson's disease (PD) stands as the second most common neurodegenerative disorder after Alzheimer's disease, and its prevalence continues to rise with the aging global population. Central to the pathophysiology of PD is the specific degeneration of midbrain dopamine neurons (mDANs) in the substantia nigra. Consequently, cell replacement therapy (CRT) has emerged as a promising treatment approach, initially supported by various open-label clinical studies employing fetal ventral mesencephalic (fVM) cells. Despite the initial favorable results, fVM cell therapy has intrinsic and logistical limitations that hinder its transition to a standard treatment for PD. Recent efforts in the field of cell therapy have shifted its focus towards the utilization of human pluripotent stem cells, including human embryonic stem cells and induced pluripotent stem cells, to surmount existing challenges. However, regardless of the transplantable cell sources (e.g., xenogeneic, allogeneic, or autologous), the poor and variable survival of implanted dopamine cells remains a major obstacle. Emerging evidence highlights the pivotal role of host immune responses following transplantation in influencing the survival of implanted mDANs, underscoring an important area for further research. In this comprehensive review, building upon insights derived from previous fVM transplantation studies, we delve into the functional ramifications of host immune responses on the survival and efficacy of grafted dopamine cells. Furthermore, we explore potential strategic approaches to modulate the host immune response, ultimately aiming for optimal outcomes in future clinical applications of CRT for PD.

cell biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the low survival rate and large variation of transplanted midbrain dopamine neurons (mDANs) in cell replacement therapy (CRT) for Parkinson's disease (PD). Specifically, the paper focuses on the following aspects:

1. **Review of history**: The paper first reviews the history of cell replacement therapy for Parkinson's disease, especially the research on transplantation using fetal ventral mesencephalon (fVM) cells. Although early studies showed certain efficacy, these studies also exposed many problems, such as inconsistent clinical effects and low survival rate of transplanted cells.

2. **Analysis of reasons**: The paper elaborately explores the reasons for the poor transplantation effect of fVM cells, including cell death during the transplantation process and the influence of the host immune response. In particular, in the early stage after transplantation, most of the transplanted mDANs die within one week, which may be related to the acute inflammatory response of the host.

3. **New directions**: In view of the limitations of fVM cell transplantation, researchers turn to using human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs). The paper discusses the advantages and challenges of using hPSCs, especially how to improve the survival rate and functional integration of transplanted cells.

4. **Importance of immune response**: The paper emphasizes the crucial role of the host immune response in the survival of transplanted cells. The response of the host immune system to transplanted cells may lead to transplantation failure, so further research is needed on how to regulate the host immune response to improve the survival rate and treatment effect of transplanted cells.

5. **Future strategies**: Finally, the paper proposes several potential strategies to improve the survival rate and function of transplanted cells, including optimizing cell culture conditions, improving cryopreservation techniques, reducing surgical delay time, and regulating the host immune response.

In summary, this paper aims to review and analyze past fVM cell transplantation studies and propose new methods and strategies to overcome the limitations of existing cell replacement therapies, and ultimately achieve more effective treatment of Parkinson's disease.